Valuation: Luoxin Pharmaceuticals Group Stock Co., Ltd.

Market Cap 5.22B 778M 687M 650M 589M 1.1B 74.65B 1.12B 7.79B 3B 38.12B 2.92B 2.86B 123B P/E 2024
-4.2x
P/E 2025 -17.7x
Enterprise Value 5.76B 859M 758M 717M 650M 1.22B 82.42B 1.23B 8.6B 3.32B 42.09B 3.23B 3.16B 135B EV / Sales 2024
1.98x
EV / Sales 2025 2.48x
Free-Float
59.59%
Yield 2024 *
-
Yield 2025 -
08-20 Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
05-20 Luoxin Pharma's Unit Fined 1.9 Million Yuan for Substandard Drug; Shares Up 3% MT
04-22 Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
01-30 Luoxin Pharmaceuticals Group Stock Co., Ltd. Elects Zuo Min, Independent Director CI
12-22 Helix Healthcare BV entered into a binding agreement to acquire an additional 20% stake in Luoxin Aurovitas Pharma Co. Ltd from Luoxin Pharmaceuticals Group Stock Co., Ltd. for $5.1 million. CI
25-10-27 Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-09-29 Luoxin Pharmaceuticals Group Stock plans to raise fund via share private placement RE
25-09-28 Luoxin Pharmaceuticals Group Stock Co., Ltd. announced that it expects to receive CNY 842.4 million in funding CI
25-09-09 Luoxin Pharmaceuticals CFO Resigns MT
25-08-27 Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-07-27 Zhongjue Zhongju Zengli No. 1 Private Securities Investment Fund managed by Shanghai Zhongjue Private Fund Management Co., Ltd. completed the acquisition of 5% stake in Luoxin Pharmaceuticals Group Stock Co., Ltd. from Chengdu Deyi Xinhua Equity Investment Partnership Enterprise (LP), Karamay Deyi Hengjia Equity Investment Limited Partnership Enterprise and Deyi Investment Management Co., Ltd. CI
25-05-28 Luoxin Pharmaceuticals Gets China's Regulatory Approval for Ibuprofen Injection Solution MT
25-05-19 Luoxin Pharmaceuticals' Shareholders Cancel Share Disposal Deal MT
1 day+1.05%
1 week-1.84%
Current month-0.83%
1 month-5.14%
3 months+19.70%
6 months+0.42%
1 week 4.62
Extreme 4.62
4.92
1 month 4.39
Extreme 4.39
5.01
Current year 3.7
Extreme 3.7
5.75
1 year 3.7
Extreme 3.7
5.84
3 years 3.22
Extreme 3.22
6.74
5 years 3.22
Extreme 3.22
11.45
10 years 3.22
Extreme 3.22
18.89
Manager TitleAgeSince
Chief Executive Officer 40 2023-04-22
Director of Finance/CFO 43 2025-09-07
Investor Relations Contact - -
Director TitleAgeSince
Chairman 40 2020-04-22
Director/Board Member 51 2020-04-22
Director/Board Member 38 2020-04-22
Date Insider Type Main position Quantity % Market Cap. Importance
3/26/20 Buy

Director

10,100 0.0041%
Change 5-day change 1-year change 3-year change Capi.($)
+1.05%-1.84%-4.57%-14.13% 778M
-0.01%+1.24%+63.06%+120.55% 1,056B
-1.61%-0.60%+47.32%+71.79% 645B
-1.12%-0.72%+17.98%+76.63% 465B
+0.16%-3.69%+34.59%+41.02% 335B
+0.18%+3.08%+21.07%+29.83% 275B
-0.64%-0.71%+10.37%+12.71% 255B
+1.32%+3.27%+54.63%+57.63% 229B
-0.61%-0.91%+34.33%+101.87% 188B
-0.74%-1.17%-27.67%-60.85% 169B
Average -0.13%-0.30%+25.11%+43.70% 361.7B
Weighted average by Cap. -0.11%+0.24%+38.64%+70.90%

Financials

2024 2025
Net sales 2.65B 394M 348M 329M 299M 560M 37.85B 566M 3.95B 1.52B 19.33B 1.48B 1.45B 62.21B 2.27B 339M 299M 283M 257M 481M 32.51B 486M 3.39B 1.31B 16.6B 1.27B 1.24B 53.42B
Net income -965M -144M -127M -120M -109M -204M -13.81B -206M -1.44B -555M -7.05B -540M -528M -22.69B -289M -43M -37.95M -35.91M -32.56M -61.05M -4.13B -61.65M -431M -166M -2.11B -161M -158M -6.78B
Net Debt 1.18B 176M 155M 147M 133M 250M 16.91B 253M 1.76B 680M 8.63B 662M 647M 27.78B 544M 81.02M 71.5M 67.65M 61.35M 115M 7.77B 116M 812M 313M 3.97B 304M 298M 12.78B
Logo Luoxin Pharmaceuticals Group Stock Co., Ltd.
Luoxin Pharmaceuticals Group Stock Co Ltd is a China-based company primarily engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on therapeutic areas such as digestive, respiratory, and anti tumor treatments. The Company's products mainly include chemical formulations, active pharmaceutical ingredients (APIs), and traditional Chinese medicines. The Company conducts its operations through two segments. The Pharmaceutical Manufacturing segment engages in the research, development, and production of chemical drug formulations and APIs, with major products including digestive medicines, respiratory medicines, and antibiotics. The Company also operates through the Pharmaceutical Distribution segment. The Company mainly operates its businesses in the domestic market.
Employees
2,962
Date Price Change Volume
26-09-29 CN¥4.800 +1.05% 31,815,700
26-09-28 CN¥4.750 +1.93% 29,055,703
26-09-24 CN¥4.660 -2.31% 19,495,800
26-09-23 CN¥4.770 -2.45% 20,725,860
26-09-22 CN¥4.890 -0.81% 33,635,239
  1. Stock Market
  2. Stocks
  3. 002793 Stock